Risks of Trazodone Similar to Those of Atypical Antipsychotics
TUESDAY, Nov. 27, 2018 -- For older adults with dementia, trazodone is associated with a comparable risk for falls and fractures as that of atypical antipsychotics, according to a study published online Nov. 26 in CMAJ, the Journal of the Canadian Medical Association.
Jennifer A. Watt, M.D., from the University of Toronto, and colleagues compared the risk for falls and fractures among older adults with dementia who received trazodone or atypical antipsychotics. The cohort included adults with dementia living in long-term care who were aged 66 years and older; 6,588 were new users of trazodone and 2,875 were new users of an atypical antipsychotic.
The researchers found that use of trazodone correlated with similar rates of falls or major osteoporotic fractures compared with use of atypical antipsychotics (weighted hazard ratio [HR], 0.89; 95 percent confidence interval [CI], 0.73 to 1.07); the rates of falls (weighted HR, 0.91; 95 percent CI, 0.75 to 1.11) and hip fractures (weighted HR, 0.92; 95 percent CI, 0.59 to 1.43) were also similar. The rate of mortality was lower in association with trazodone use (weighted HR, 0.75; 95 percent CI, 0.66 to 0.85).
"Watt and colleagues also underscore the importance of prioritizing nonpharmacological approaches for the management of behavioral and psychological symptoms of dementia," write the authors of an accompanying editorial. "Nonpharmacological approaches comprise a variety of behavioral, environmental and caregiver-supportive interventions, and existing evidence suggests that these show greater effect than many psychotropic drug therapies."
© 2020 HealthDay. All rights reserved.
Posted: November 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.